KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessShares IssuedShares Repurchased
Ratios

Vertex Pharmaceuticals (VRTX) Shares Repurchased (2018 - 2025)

Historic Shares Repurchased for Vertex Pharmaceuticals (VRTX) over the last 7 years, with Q4 2025 value amounting to $128.4 million.

  • Vertex Pharmaceuticals' Shares Repurchased fell 6927.49% to $128.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.0 billion, marking a year-over-year increase of 7138.73%. This contributed to the annual value of $2.0 billion for FY2025, which is 7138.73% up from last year.
  • Vertex Pharmaceuticals' Shares Repurchased amounted to $128.4 million in Q4 2025, which was down 6927.49% from $1.1 billion recorded in Q3 2025.
  • Vertex Pharmaceuticals' 5-year Shares Repurchased high stood at $1.1 billion for Q3 2025, and its period low was $28.3 million during Q2 2023.
  • For the 4-year period, Vertex Pharmaceuticals' Shares Repurchased averaged around $336.5 million, with its median value being $320.3 million (2024).
  • As far as peak fluctuations go, Vertex Pharmaceuticals' Shares Repurchased skyrocketed by 103180.21% in 2024, and later plummeted by 6927.49% in 2025.
  • Vertex Pharmaceuticals' Shares Repurchased (Quarter) stood at $368.2 million in 2021, then plummeted by 59.4% to $149.5 million in 2023, then soared by 179.53% to $417.9 million in 2024, then tumbled by 69.27% to $128.4 million in 2025.
  • Its last three reported values are $128.4 million in Q4 2025, $1.1 billion for Q3 2025, and $391.8 million during Q2 2025.